You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
邁克生物(300463.SZ):2020年度淨利預增40%-60%
格隆匯 01-13 17:37

格隆匯1月13日丨邁克生物(300463.SZ)披露2020年度業績預吿,預計2020年度歸屬於上市公司股東的淨利潤7.35億元-8.4億元,同比增長40%-60%。業績變動原因如下:

2020年度,新型冠狀病毒感染的肺炎疫情在全球範圍內爆發,對新冠相關檢測及防護產品的需求迅速增長,公司自主研發生產的新冠核酸檢測及抗體檢測產品的市場需求也隨之增長,促使公司分子診斷及快速檢測平台產品銷售迅速增長,隨着國內抗擊新冠肺炎疫情工作的不斷推進,國內疫情防控成果不斷鞏固,公司常規檢測產品的銷售也穩步恢復。

新冠疫情爆發以來,公司積極調整經營策略以順應外部環境變化和內部發展需求,持續補充和完善自主產品種類,加速新產品全自動化學發光免疫分析儀i1000、全自動血液分析儀F800等的上市裝機進度,繼續推進國內銷售渠道的升級優化,努力拓展海外銷售渠道,不斷提升綜合服務能力。在多重因素的綜合影響下,公司2020年業績較上年同期增長40%~60%。

報吿期內,預計非經常性損益對淨利潤的影響為2300萬元左右,主要系政府補助和新冠疫情物資捐贈。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account